Medical use of cannabis. Cannabidiol: a new light for schizophrenia?

Author(s): Deiana S

Department CNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. K., Biberach an der Riss, Germany. [email protected]

Subject: Schizophrenia View the study

Abstract:

The medical properties of cannabis have been known for many centuries; its first documented use dates back to 2800 BC when it was described for its hallucinogenic and pain-relieving properties. In the first half of the twentieth century, a number of pharmaceutical companies marked cannabis for indications such as asthma and pain, but since then its use has sharply declined, mainly due to its unpredictable effects, but also for socio-political issues. Recently, great attention has been directed to the medical properties of phytocannabinoids present in the cannabis plant alongside the main constituent Δ⁹-Tetrahydrocannabinol (THC); these include cannabinoids such as cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabivarin (THCV).

Source: Drug Testing and Analysis (Price: $38)
Share Tweet

More medical studies related to Schizophrenia:

View all medical studies >>

Subscribe for daily cannabis news, announcements, and business insights.

Видеодомофоны цветные sledoc.com.ua/
gestational surrogacy uk

шторы в зал